Matthew Kapusta Sells 6,696 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 6,696 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $50.00, for a total transaction of $334,800.00. Following the completion of the sale, the chief executive officer owned 519,227 shares of the company’s stock, valued at approximately $25,961,350. This represents a 1.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Down 3.2%

uniQure stock opened at $47.51 on Friday. The firm has a market capitalization of $3.00 billion, a PE ratio of -13.65 and a beta of 0.98. The company’s 50-day moving average is $27.84 and its 200-day moving average is $23.02. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Sell-side analysts anticipate that uniQure N.V. will post -3.65 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on QURE shares. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. TD Cowen reissued a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. HC Wainwright restated a “buy” rating on shares of uniQure in a research note on Thursday, June 18th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a report on Wednesday, June 17th. Finally, Stifel Nicolaus set a $28.00 target price on uniQure in a research report on Tuesday, May 5th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.67.

Institutional Trading of uniQure

Several large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC raised its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. Aberdeen Group plc increased its stake in shares of uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares during the last quarter. State Street Corp raised its holdings in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after buying an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its position in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after buying an additional 1,398,749 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.